drugset / Trial / NCT06817200

The Effect of Amantadine as add-on Therapy for Motor Fluctuations in Advanced Parkinson's Disease: a Randomized Double-blinded Placebo-controlled Trial

NCT06817200

Phase 2 Not yet recruiting 132 enrolled University Hospital, Toulouse
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Motor fluctuations are identified as the most challenging symptoms by parkinson disease patients. A recent post-hoc analysis of ADS-5012 trials (new formulation of ER Amantadine), revealed a significant improvement in OFF-time. No randomized clinical trial has ever specifically investigated to date the effect of amantadine IR on motor fluctuations. The main objective of this study is to evaluate the effect of amantadine (300 mg/day) as add-on therapy for the treatment of motor fluctuations (Off-time) in advanced Parkinson's disease patients versus placebo after 3 months of treatment.

Timeline

Start
2025-05-01
Primary completion
2025-05-01
Completion
2027-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Amantadine Unknown 100 mg

Indications